NCT05710328 2026-03-02
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT00929214 2025-12-17
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01723774 2025-12-09
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT07016399 2025-10-30
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT04997941 2024-04-23
MORE-T
Seoul National University Hospital
Phase 2 Active not recruiting
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02636582 2023-12-05
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02891759 2023-05-06
Compare Outcomes Between Two Acellular Dermal Matrices
Washington University School of Medicine
Phase 2 Completed
NCT04698252 2022-08-08
LARA
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04398914 2022-03-31
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT01847001 2021-09-10
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Columbia University
Phase 2 Completed
NCT04066790 2020-05-19
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Terminated
NCT00944047 2018-04-23
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
University of Kansas Medical Center
Phase 2 Completed
NCT01142778 2018-03-16
AVATAXHER
Hoffmann-La Roche
Phase 2 Completed
NCT00855114 2017-12-02
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01368263 2015-04-03
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00003050 2014-05-22
Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
University of Southern California
Phase 2 Completed
NCT00849472 2014-03-04
Treatment With Pazopanib for Neoadjuvant Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00080613 2013-07-10
Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00082667 2013-02-25
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00003953 2013-01-28
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00005800 2012-09-25
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00003035 2011-03-24
Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
Georgetown University
Phase 2 Completed
NCT00191789 2010-07-27
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
Eli Lilly and Company
Phase 2 Completed